The Commission Opens Investigation Into Possible Anticompetitive Disparagement by Vifor Pharma of Iron Medicine

The European Commission (“the Commission”) has opened a formal antitrust investigation to assess whether Vifor Pharma has restricted competition by illegally disparaging its closest – and potentially only – competitor in Europe on the market for intravenous iron treatment, Pharmacosmos.

Vifor Pharma's conduct appears to be aimed at hindering competition against its blockbuster high-dose intravenous iron treatment medicine, Ferinject.

The Commission is concerned that Vifor Pharma pursued a misleading communication campaign, primarily targeting healthcare professionals, which may have unduly hindered Monofer's uptake in the European Economic Area (‘EEA'). Approximately 1.8 million patients suffering from iron deficiency are currently being treated with high-dose intravenous iron products annually in the EEA.

You can reach further information here.

Kind regards,

Zumbul Attorneys at Law

info@zumbul.av.tr